How Guardant360 CDx approval supports Boehringer Ingelheim’s HERNEXEOS launch strategy
Find out how Guardant360 CDx approval could expand liquid biopsy use in HER2-mutant advanced lung cancer treatment selection.
Medical Devices & Diagnostics
Pharma & Biotech
How Celltrion’s HER2–CD3 bispecific could compete in the T-cell engager arena
Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.